Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus Cadila gets final nod from USFDA for Carboplatin injection
Cadila Healthcare (Zydus Cadila) on Friday informed that the company has recieved the final approval from the US drug regulator, USFDA to market Carboplatin Injection, 10 mg/ml in 5 ml, 15 ml and 45 ... Zydus receives final approval from the USFDA for Carboplatin Injection
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated April 01, 2016 titled "Zydus receives final approval from the USFDA for Carboplatin Injection". Gujarat State TB Association, Sparsh and Cadila Pharma organise medical camps
Awareness was raised on tuberculosis where more than 300 villagers underwent health checkups and were given consultations Zydus Nesher Pharmaceuticals receives its first ANDA approval for Dextroamphetamine IR Tabs
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 30, 2016 titled "Zydus Nesher Pharmaceuticals receives its first ANDA approval for Dextroamphetamine IR Tabs". Zydus Cadila gets USFDA nod to market Acyclovir capsules
The group now has more than 100 approvals Zydus receives final approval from the USFDA for Acyclovir Capsules USP
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 29, 2016 titled "Zydus receives final approval from the USFDA for Acyclovir Capsules USP". Zydus acquires the gastro therapy 'Actibile from Albert David Limited, Strengthens its presence in the gastroenterology segment
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 28, 2016 titled "Zydus acquires the gastro therapy 'Actibile from Albert David Limited, Strengthens its presence in the gastroenterology segment".
Cadila gets WHO warning for its Moraiya vaccine plant in Gujarat
The world body, in its inspection from 26-30 October, found data integrity issues at the plant that manufactures Lyssavac-N, an anti-rabies vaccine Clarification
Cadila Healthcare Ltd has informed BSE that:"There have been some reports regarding the pre-qualification plant inspection of the vaccines facility by WHO in terms of the possible linkage with our oral solids and injectable facilities at the Moraiya manufacturing complex.In this regard, we hereby inform that we have a separate manufacturing facility for vaccines and this does not form a part of the oral solids and injectable facilities...